Corbus Pharmaceuticals Holdings, Inc.
(NASDAQ : CRBP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 3.51%52.430.9%$1363.76m
JNJJohnson & Johnson 1.74%176.970.7%$1352.49m
BMYBristol-Myers Squibb Co. 0.36%76.231.0%$1197.90m
ABBVAbbVie, Inc. -0.53%150.921.9%$1137.44m
MRKMerck & Co., Inc. 1.26%93.250.7%$1136.00m
LLYEli Lilly & Co. 4.49%299.111.1%$892.99m
AZNAstraZeneca Plc 2.59%66.211.0%$517.65m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.65%141.960.0%$458.27m
VERUVeru, Inc. -6.37%13.380.0%$318.66m
NVSNovartis AG 0.86%89.410.2%$251.17m
GSKGlaxoSmithKline Plc 2.23%44.530.2%$243.21m
HZNPHorizon Therapeutics Plc 1.13%90.355.4%$200.40m
NVONovo Nordisk A/S 3.49%107.680.1%$190.60m
SGENSeagen Inc. -2.10%139.645.7%$181.75m
VTRSViatris, Inc. 0.94%11.800.0%$166.13m

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.